HNMVX
Price
$32.06
Change
+$0.15 (+0.47%)
Updated
Jun 2 closing price
Net Assets
434.41M
JVMRX
Price
$29.43
Change
+$0.26 (+0.89%)
Updated
Jun 2 closing price
Net Assets
22.49B
Interact to see
Advertisement

HNMVX vs JVMRX

Header iconHNMVX vs JVMRX Comparison
Open Charts HNMVX vs JVMRXBanner chart's image
HNMVX vs JVMRX Comparison Chart in %
View a ticker or compare two or three
VS
HNMVX vs. JVMRX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HNMVX is a StrongBuy and JVMRX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JVMRX has more cash in the bank: 22.5B vs. HNMVX (434M). HNMVX pays higher dividends than JVMRX: HNMVX (1.21) vs JVMRX (0.81). HNMVX was incepted earlier than JVMRX: HNMVX (10 years) vs JVMRX (15 years). HNMVX (0.82) is less costly to investors than JVMRX (0.75). JVMRX is a more actively managed with annual turnover of: 49.00 vs. HNMVX (20.00). HNMVX (1000000) and JVMRX (1000000) have matching initial minimum investment requirements. HNMVX annual gain was more profitable for investors over the last year : 27.06 vs. JVMRX (7.17). HNMVX return over 5 years is better than : 29.59 vs. JVMRX (5.11).
HNMVXJVMRXHNMVX / JVMRX
Total Expense Ratio0.770.74104%
Annual Report Gross Expense Ratio0.820.75109%
Fund Existence10 years15 years-
Gain YTD16.1636.227260%
Front LoadN/AN/A-
Min. Initial Investment10000001000000100%
Min. Initial Investment IRAN/AN/A-
Net Assets434M22.5B2%
Annual Yield % from dividends1.210.81150%
Returns for 1 year27.067.17377%
Returns for 3 years48.5320.52236%
Returns for 5 years29.595.11579%
Returns for 10 years81.0654.85148%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CGTX1.340.09
+7.20%
Cognition Therapeutics
VIV13.490.30
+2.27%
Telefonica Brasil SA
CHEF77.680.71
+0.92%
Chefs' Warehouse (The)
BBOT8.24-0.31
-3.63%
BridgeBio Oncology Therapeutics Inc
APVO5.02-0.22
-4.20%
Aptevo Therapeutics Inc